• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

New therapy for patients with heavy menstrual bleeding

News
Article

An oral dose of modified-release tranexamic acid may offer an effective first-line therapy for patients with heavy menstrual bleeding, according to a recent study published online July 17 in The Annals of Pharmacotherapy.

An oral dose of modified-release (MR) tranexamic acid may offer an effective first-line therapy for patients with heavy menstrual bleeding, according to a recent study published online July 17 in The Annals of Pharmacotherapy.

Sandra L Hrometz, BSPharm, PhD, CGP, professor of pharmacology in the Department of Pharmaceutical and Biomedical Sciences at Raabe College of Pharmacy, Ohio Northern University, in Ada, Ohio, examined past published studies as well as data from FDA to examine the efficacy and safety profile of the oral MR formulation.

She identified 2 clinical trials from which to evaluate efficacy, 3 clinical trials from which to evaluate change in quality of life, and 4 clinical trials from which to evaluate safety.

Her findings showed that tranexamic acid interferes with the binding of plasminogen to fibrin, which results in enhanced fibrin clot integrity. The oral dose can safely and effectively begin at the start of a heavy menstrual cycle and can be taken for up to 5 days per cycle.

She noted that doses may need to be adjusted for women with renal insufficiency. The most common adverse effects were menstrual discomfort, headache, and back pain; however, they were not severe. The most significant safety concerns were related to the risk of thromboembolism.

“MR tranexamic acid offers a new first-line therapy for patients with cyclic heavy menstrual bleeding. It is reported to be safe and effective,” Dr Hrometz wrote in the abstract, adding, “There are no labeled equivalents to MR tranexamic acid for cyclic heavy menstrual bleeding.”

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.